

Financial Times: Insys case raises risks for drug industry over opioids

Co-Founder and Managing Partner [Harry Nelson](#) was interviewed by the [Financial Times](#) regarding the recent Insys Trial and the conviction of the company's top executives for opioid racketeering. Harry discusses the significance of this case and what it means for the future of criminal prosecutions of drug manufacturers and distributors.

From the article:

Harry Nelson, the managing partner of healthcare law firm NelsonHardiman and the author of [The United States of Opioids: A Prescription for Liberating a Nation in Pain](#), said he expects the government to redouble its efforts to pursue criminal prosecutions.

"[The Insys case] is obviously a significant moment in actually getting a criminal conviction against an opioid drugmaker," he said, adding that he expects prosecutors to "revisit" the case of leadership at Purdue Pharma, the maker of OxyContin that is owned by the Sackler family.

[Read the full article](#)